D-0270-2025 Class II Ongoing

Recalled by Breckenridge Pharmaceutical, Inc. — Berkeley Heights, NJ

FDA drug recall D-0270-2025 was initiated by Breckenridge Pharmaceutical, Inc. on Feb 28, 2025 and is designated Class II. Reason for recall: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. The recall status is ongoing. Affected quantity: 14,749 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 19, 2025
Initiation Date
Feb 28, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
14,749 bottles.

Product description

Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 1000-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-747-10

Reason for recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Distribution pattern

Nationwide

Code information

Lot#: 240225C, Expiration: 01/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0270-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0270-2025. Report a data issue: hello@regdatalab.com.